pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

422 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165BioSpace64Fierce Biotech64raps29
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Viridian data lift prospects for thyroid eye disease drug
    <figure><div><img src="https://imgproxy.divecdn.com/egbyTu8esim-VjYj5FTvMQUlBrndW-s35OSn02s-EoY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzk4NTE5MTYzLmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[The Type of Fat—Not the Amount—Fuels Pancreatic Cancer]]>
    <![CDATA[Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia]]>
    <![CDATA[Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.]]>
← prev
page 16 of 17
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • <![CDATA[Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC ]]>
    <![CDATA[Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis]]>
    <![CDATA[Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.]]>
    onclive · 2mo ago↗ source
  • Vertex earnings get muted investor response
    <p>While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.</p>
    BioPharma Dive · 2mo ago↗ source
  • Cytokinetics heart drug scores in closely watched trial
    <figure><div><img src="https://imgproxy.divecdn.com/O5l3Ak2w-ITPZwAy2_UP-yuYAxNqpRx2E-yOxBQdi8M/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy05MzA1MTIzNTAuanBn.…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[New Endometrial Targets Beyond HER2]]>
    <![CDATA[Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE…
    onclive · 2mo ago↗ source
  • <![CDATA[Coordinating Care in Multiple Myeloma Across Practice Settings ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression]]>
    <![CDATA[In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosi…
    onclive · 2mo ago↗ source
  • <![CDATA[New Understandings of Treatments, End Points, and Disease Biology Expand MCL Horizons]]>
    <![CDATA[Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.]]>
    onclive · 2mo ago↗ source
  • Cytospire hauls in $83M for a new type of T cell engager
    <p>The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies. </p>
    BioPharma Dive · 2mo ago↗ source
  • Celcuity strengthens case for ASCO-spotlighted breast cancer drug
    <figure><div><img src="https://imgproxy.divecdn.com/1TNhYQTUI7yObB637nFZIAJqv_C_vHe6B8CqUtpkWHg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQwMTQ3MDc2LmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • With $97M, Latus pursues a different kind of Huntington’s gene therapy
    <figure><div><img src="https://imgproxy.divecdn.com/G3XsVcjEEsY7RUeeyuhDwfcUgL9AKu_uzJpv0LpcZ60/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQ4MTMyNzUyLmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases
    <p>The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.</p>
    BioPharma Dive · 2mo ago↗ source
  • What is your AI drug repurposing strategy missing?
    <p>Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.</p>
    BioPharma Dive · 2mo ago↗ source
  • Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
    <figure><div><img src="https://imgproxy.divecdn.com/xFVDAUb89QQFVPrJL8faaWdXxcY16WqAOJqd9TV5Hi0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzY5MDAzNjAwLmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 2mo ago↗ source
  • Moderna sees revenue bump from international COVID vaccine sales
    <figure><div><img src="https://imgproxy.divecdn.com/OJs2JMlOuL6tHcK-0IUh-ddLSEy1yS6jzGMiAhl9CGY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjg4NjcwMjY5LmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
    <figure><div><img src="https://imgproxy.divecdn.com/v0D5Ajbuzjf7G4SQRuR5yVFGXoGWXxkevKZwUQRcJjs/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTU2MTc2MTM5LmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • Two biotechs raise a combined $556M in latest spurt of IPOs
    <figure><div><img src="https://imgproxy.divecdn.com/Ll8Kl4Xj3nHdTKBGSRbP6tU2Gjn-xo-ocHpjXqrNGQQ/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDAxNzQ1Njc1LmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • Merck still sees ‘compelling’ outlook for Terns leukemia drug
    <figure><div><img src="https://imgproxy.divecdn.com/xfbigDwOXtNIbcSDIg7fJNLgHOwkgMuxa4LD4r3ON-0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9TY3JlZW5zaG90XzIwMjQtMTItMTlfMTAzN…
    BioPharma Dive · 2mo ago↗ source
  • UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy
    <figure><div><img src="https://imgproxy.divecdn.com/KzTgmqusVHa-I1RJqlROBuSgo45i9g_dBOqQI8x92Z4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80Y2QwNGU1YS1lNmEyLTQ2OWUtOGVkMS1mO…
    BioPharma Dive · 2mo ago↗ source
  • Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
    <figure><div><img src="https://imgproxy.divecdn.com/LUU4XfIR8eFQgmY5HrlCjsI3-Klo8riH1u1jZ_W_2D4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9MaWxseV9PRkdfQm90dGxlX1RhYmxldF9HM…
    BioPharma Dive · 2mo ago↗ source
  • Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
    <figure><div><img src="https://imgproxy.divecdn.com/ok5MPeEmVJIiNJX2QcG0yjZjnAkPtgyl-6RiUb3-HFc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDUwNzUwNzQzLmpwZ…
    BioPharma Dive · 2mo ago↗ source